Samson Rock Capital’s AbbVie ABBV Stock Holding History

Samson Rock Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,980	Closed	-$266K	–	20
2022 Q3	$266K	Buy	+1,980	New	+$284K	0.2%	29

Other funds holding ABBV

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Samson Rock Capital's ABBV Position: Q4 2022 in Review

Samson Rock Capital sold out of AbbVie (ABBV) in Q4 2022, closing a stake of 1,980 shares — an estimated $266K sold.

Samson Rock Capital first reported a position in ABBV in Q3 2022 and held it in 1 quarter. The position peaked at $266K in Q3 2022. 3,168 funds tracked by Wall St. Rank hold ABBV as of Q4 2022.

Samson Rock Capital reported no remaining AbbVie position as of Q4 2022 after selling out during the quarter.
Samson Rock Capital sold 1,980 AbbVie shares in Q4 2022, an estimated $266K.
Samson Rock Capital first reported a position in AbbVie in Q3 2022 and held it in 1 quarter.
Samson Rock Capital's AbbVie position peaked at $266K in Q3 2022.
3,168 funds tracked by Wall St. Rank held AbbVie as of Q4 2022.

Based on Samson Rock Capital's 13F filing for Q4 2022, filed 7 Feb 2023.